Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Evogene (EVGN) EBITDA (2016 - 2025)

Historic EBITDA for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to -$2.7 million.

  • Evogene's EBITDA rose 5398.65% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.5 million, marking a year-over-year increase of 3492.34%. This contributed to the annual value of -$18.8 million for FY2024, which is 2906.29% up from last year.
  • Evogene's EBITDA amounted to -$2.7 million in Q3 2025, which was up 5398.65% from -$3.1 million recorded in Q2 2025.
  • Evogene's EBITDA's 5-year high stood at -$2.7 million during Q3 2025, with a 5-year trough of -$8.7 million in Q4 2021.
  • In the last 5 years, Evogene's EBITDA had a median value of -$6.3 million in 2021 and averaged -$6.0 million.
  • Per our database at Business Quant, Evogene's EBITDA skyrocketed by 5648.87% in 2022 and then crashed by 10169.22% in 2023.
  • Quarter analysis of 5 years shows Evogene's EBITDA stood at -$8.7 million in 2021, then soared by 56.49% to -$3.8 million in 2022, then plummeted by 101.69% to -$7.6 million in 2023, then skyrocketed by 40.13% to -$4.6 million in 2024, then surged by 40.35% to -$2.7 million in 2025.
  • Its EBITDA was -$2.7 million in Q3 2025, compared to -$3.1 million in Q2 2025 and -$4.1 million in Q1 2025.